JP2023515131A5 - - Google Patents

Info

Publication number
JP2023515131A5
JP2023515131A5 JP2022550741A JP2022550741A JP2023515131A5 JP 2023515131 A5 JP2023515131 A5 JP 2023515131A5 JP 2022550741 A JP2022550741 A JP 2022550741A JP 2022550741 A JP2022550741 A JP 2022550741A JP 2023515131 A5 JP2023515131 A5 JP 2023515131A5
Authority
JP
Japan
Prior art keywords
cells
cancer
cell
human
feeder cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515131A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/019252 external-priority patent/WO2021173560A1/en
Publication of JP2023515131A publication Critical patent/JP2023515131A/ja
Publication of JP2023515131A5 publication Critical patent/JP2023515131A5/ja
Pending legal-status Critical Current

Links

JP2022550741A 2020-02-24 2021-02-23 がんおよび関連する悪性腫瘍の治療のためにt細胞を増殖させる方法 Pending JP2023515131A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062980844P 2020-02-24 2020-02-24
US62/980,844 2020-02-24
US202063038008P 2020-06-11 2020-06-11
US63/038,008 2020-06-11
US202063082881P 2020-09-24 2020-09-24
US63/082,881 2020-09-24
PCT/US2021/019252 WO2021173560A1 (en) 2020-02-24 2021-02-23 Methods for expanding t cells for the treatment of cancer and related malignancies

Publications (2)

Publication Number Publication Date
JP2023515131A JP2023515131A (ja) 2023-04-12
JP2023515131A5 true JP2023515131A5 (cg-RX-API-DMAC7.html) 2024-01-22

Family

ID=74875356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550741A Pending JP2023515131A (ja) 2020-02-24 2021-02-23 がんおよび関連する悪性腫瘍の治療のためにt細胞を増殖させる方法

Country Status (12)

Country Link
US (1) US20250002855A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110901A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023515131A (cg-RX-API-DMAC7.html)
KR (1) KR20230012465A (cg-RX-API-DMAC7.html)
CN (1) CN115427554A (cg-RX-API-DMAC7.html)
AU (1) AU2021225817A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016909A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168729A1 (cg-RX-API-DMAC7.html)
IL (1) IL295891A (cg-RX-API-DMAC7.html)
MX (1) MX2022010461A (cg-RX-API-DMAC7.html)
TW (1) TW202146645A (cg-RX-API-DMAC7.html)
WO (1) WO2021173560A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312734A (en) * 2021-11-12 2024-07-01 Janssen Biotech Inc Materials and methods for improved expansion and uses of immune cells
EP4433068A4 (en) * 2021-11-18 2025-11-12 Univ Minnesota LARGE-SCALE MULTIPLICATION OF MODIFIED HUMAN GAMMA T LYMPHOCYTES
KR20230105166A (ko) * 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
GB202204926D0 (en) * 2022-04-04 2022-05-18 Gammadelta Therapeutics Ltd Method for expanding gammadelta T cells
WO2023250336A1 (en) * 2022-06-21 2023-12-28 Kiromic BioPharma, Inc. Methods for generating gamma delta t-cells and related compositions
WO2025067472A1 (en) * 2023-09-27 2025-04-03 Nanjing Legend Biotech Co., Ltd. Methods of culturing gamma delta t cells
WO2026126652A1 (ja) * 2024-12-13 2026-06-18 学校法人藤田学園 抗CD38 CAR-γδT細胞

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
AU3940293A (en) 1992-04-03 1993-11-08 Alexander T. YOUNG Gene therapy using targeted viral vectors
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
DK0973928T3 (da) 1997-03-11 2010-08-09 Univ Minnesota DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
WO2003089618A2 (en) 2002-04-22 2003-10-30 Regents Of The University Of Minnesota Transposon system and methods of use
US9840695B2 (en) 2009-04-28 2017-12-12 Agriculture Victoria Services Pty Ltd Plant technology
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
KR20170021354A (ko) * 2014-07-02 2017-02-27 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) CD1d 제한된 감마/델타 T 세포 림프종을 진단 및 치료하는 방법
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US10159726B2 (en) 2015-08-28 2018-12-25 Immatics Biotechnologies Gmbh Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
WO2017060201A1 (en) 2015-10-09 2017-04-13 Immatics Biotechnologies Gmbh Anti-wt1/hla-specific antibodies
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
GB201604494D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers
EP4357454A3 (en) 2016-03-16 2024-07-24 Immatics Biotechnologies GmbH Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
HRP20221375T1 (hr) 2016-03-16 2023-01-06 Immatics Biotechnologies Gmbh Transfecirane t-stanice i t-stanični receptori za upotrebu u imunoterapiji protiv raka
GB201604492D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
CN118421557A (zh) * 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
ZA201900664B (en) 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
DE102016115246C5 (de) 2016-08-17 2018-12-20 Immatics Biotechnologies Gmbh Neue t-zellrezeptoren und deren verwendung in immuntherapie
KR102397771B1 (ko) * 2016-09-23 2022-05-13 프레드 헛친슨 켄서 리서치 센터 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도
EP3300863B1 (en) 2016-09-28 2020-06-17 Braun GmbH Electric shaver
KR102032354B1 (ko) * 2016-11-11 2019-10-16 가톨릭대학교 산학협력단 신규한 배양보조세포 및 이를 이용한 감마 델타 t 세포의 증식 방법
DE102016123847B3 (de) 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
MY200528A (en) * 2017-02-08 2023-12-30 Agency Science Tech & Res Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
DE102017114737A1 (de) 2017-06-30 2019-01-03 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
GB201715918D0 (en) * 2017-09-29 2017-11-15 Tc Biopharm Ltd Modified CAR-T
WO2019086665A1 (en) 2017-11-06 2019-05-09 Immatics Biotechnologies Gmbh Novel engineered t cell receptors and immune therapy using the same
DE102017127984B4 (de) * 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
CN109234236A (zh) * 2018-09-29 2019-01-18 吉林大学第医院 一种嵌合抗原受体γδT细胞的制备方法
AU2020286756A1 (en) 2019-06-06 2022-01-27 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides

Similar Documents

Publication Publication Date Title
JP7653962B2 (ja) 濃縮された腫瘍反応性t細胞集団を腫瘍から作製する方法
JP6944497B2 (ja) 新規に単離された細胞の治療組成物の操作および送達
JP6833727B2 (ja) 細胞
AU2024201332B2 (en) Enhancer for t-cells or b-cells having memory function, malignant tumor recurrence inhibitor, and inducer for inducing memory function in t-cells or b-cells
CN106459917B (zh) 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
US20230248825A1 (en) T-cells expressing immune cell engagers in allogenic settings
JP2016183194A (ja) 細胞免疫療法のための方法および組成物
CN111727242A (zh) 用于活化、修饰和扩增γδT细胞治疗癌症和相关恶性肿瘤的方法
TW201945013A (zh) 製備和使用引導及導航控制蛋白之方法
EP4273233A2 (en) Mr1 restricted t cell receptors for cancer immunotherapy
JP7863702B2 (ja) 表現型特性が向上したt細胞組成物
US20240216426A1 (en) Recombinant antigen presenting cells
Streltsova et al. Current approaches to engineering of NK cells for cancer immunotherapy
CN114599784A (zh) 具有cd45ra+和ccr7+的细胞表面标志物的t细胞的制备方法
IT202300027432A1 (it) Cellule nk geneticamente modificate per il trattamento di tumori e malattie autoimmuni
EP4212618A1 (en) Method of producing vdelta1+ t cells
Kebriaei et al. CARs: driving T-cell specificity to enhance anti-tumor immunity
CA3141210A1 (en) Modified nk-92 cells, and therapeutic and diagnostic uses thereof
CN115461361B (zh) 嵌合抗原受体和携带该受体的经修饰的细胞
CN120344654A (zh) 改造的自然杀伤细胞和相关方法
Guedan et al. CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition
Magnani et al. PF436 GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY
WO2026069206A1 (en) Hypoimmunogenic modified gamma delta t cells
KR20260026056A (ko) 시험관 내에서 유래된 t 세포 모집단, 이의 생성 방법, 및 사용 방법
CN120758458A (zh) 改造的免疫细胞、靶向Prdm12基因的gRNA和应用